|
1 OECD
Health Data
Paris, 2002
5 FUCHS, V. (1996)
“Economics, values and health care reform”
American Economics Review, March, 1-24.
CUTLER, D., M. McCLELLAN (1996)
“The determinants of technological change in heart attack treatment”.
Working paper 5751, New Working Paper Series, National Bureau of Economic
Research. The same authors later found that the total benefits of technological
change exceeded the corresponding costs for at least four of the five
conditions over the period studied (findings for breast cancer were equivocal)
( CUTLER, D., M. McCLELLAN (2001), “Is technological change in medicine
worth it?”
Health Affairs 2001; 20: 11-29).
|
2 OECD
Towards High-Performing Health Systems
Paris, 2004
3 AARON, H. (1991)
Serious and unstable condition: financing America’s health care
Washington, D.C.: The Brookings institute.
6 OECD
Health Technology and Decision Making, OECD, Paris, forthcoming
#. HTAi has recently been established replacing the International Society
for Technology Assessment in Health Care (ISTAHC) which became insolvent.
#. www.inahta.org
#. This specific division is not universally agreed; for example in some
circumstances appraisal and decision making may be conducted by the same
people. The important point is that review, appraisal and decision are
conceptually distinct parts of a HTA-supported process.
|
4 NEWHOUSE, J.P. (1992)
Medical care costs: how much welfare loss?
Journal of Economic Perspectives 1992; 6: 3 21.
7
The original intention was to include a pharmaceutical-based technology
in the set of case studies. However, no agreement was reached on an appropriate
methodology for such a case study.
8 DICKSON, M, J. HURST AND S. JACOBZONE (2003) “Survey
of pharmacoeconomic assessment activity in eleven countries
OECD Health Working Papers
|